The company’s earnings beat expectations, driven by strong domestic and international demand, while a new share‑repurchase program signals confidence in cash flow.
ResMed’s Q2 results show strong revenue and margin growth, fueled by new products and a positive impact from GLP-1 medications on CPAP adoption.